Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes
Source : https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2023.667
Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes
Conclusion: Our design panel can detect many actionable gene mutations, including those at low frequency. Therefore, liquid biopsy can be applied clinically in the evaluation of lymphoma patients, especially in aggressive lymphoma patients.
Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37407018/
Case 11-2023: A Man with Mantle-Cell Lymphoma and Hypoxemia
Relevance: Schmidt and colleagues provide a logical rationale for administering methylene blue therapy in a patient with hypoxemia caused by dapsone-induced methemoglobinemia.
Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37420136/
We conducted two indirect comparisons to estimate the efficacy of zanubrutinib versus orelabrutinib in Chinese patients with relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or R/R mantle...
Conclusions/Relevance: Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors
Source : https://haematologica.org/article/view/haematol.2022.282469
Le Gouill S, Długosz-Danecka M, Rule S, Zinzani PL, Goy A, Smith SD, Doorduijn JK, Panizo C, Shah BD, Davies AJ, Eek R, Jacobsen E, Kater AP, Robak T, Jain...
Conclusions/Relevance: The final results of this study with 38.1 months median follow-up support the use of acalabrutinib in patients with R/R MCL, including those with high-risk features such as blastoid/pleomorphic variants, high-risk MIPI score, and Ki-67 index >50%, and demonstrated a consistent safety profile. Ongoing studies are...
Clinical applications of circulating tumor DNA in indolent B-cell lymphomas
Source : https://www.sciencedirect.com/science/article/abs/pii/S0037196323000501?via=ihub
Indolent B-cell lymphomas are generally incurable with standard therapy and most patients have a prolonged disease course that includes multiple treat...
Conclusion: Clinical studies have established the prognostic value of ctDNA as a measure of MRD at landmark timepoints in both FL and MCL, but the clinical utility of making treatment decisions on the presence of MRD remains unproven. The lack of identification of a molecular marker in a sizeable number of patients combined with relatively...